# A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

> **NCT05187832** · PHASE1 · RECRUITING · sponsor: **Kind Pharmaceuticals LLC** · enrollment: 61 (estimated)

## Conditions studied

- Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** AND019 PO QD

## Key facts

- **NCT ID:** NCT05187832
- **Lead sponsor:** Kind Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-05
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05187832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05187832, "A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05187832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*